Skip to main content

ESTUDIO INTEGRATIVO DE LA INFLAMACION SISTEMICA EN DERMATITIS ATOPICA E HIDRADENITIS SUPURATIVA Y SU ASOCIACIÓN CON LA ENFERMEDAD CARDIOVASCULAR

PI21/01583

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INVESTIGACION BIOMEDICA HOSPITAL DE LA PRINCESA
Execution centre INSTITUTO DE INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO DE LA PRINCESA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice

  • Butrón-Bris, B.
  • Llamas-Velasco, Mar|||0000-0002-1187-1341
  • Ovejero-Benito, M.C.
  • Santos-Juanes, Jorge|||0000-0001-5578-3522
  • Martínez-López, A.
  • Ruíz Villaverde, Ricardo|||0000-0002-0381-6174
  • Roustan, G.
  • Baniandrés Rodríguez, Ofelia|||0000-0001-8183-3941
  • Izu, Rosa Maria
  • De la Cueva, Pablo|||0000-0003-4807-3551
  • Sahuquillo-Torralba, A.
  • González Quesada, Alicia
  • Vilarrasa-Rull, Eva|||0000-0001-6507-0534
  • Pujol-Montcusí, J.
  • García-Martínez, J.
  • Navares, M.
  • Palomar-Moreno, I.
  • Novalbos, J.
  • Abad-Santos, Francisco|||0000-0002-6519-8885
  • Daudén, E.
  • Fuente, Hortensia de la
Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real-life clinical practice. Ninety patients with plaque psoriasis recruited from-Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms. Optimal response to tildrakizumab was evaluated by absolute PASI ≤1 at 6 and 12 months. Polymorphisms corrected for weight and disease duration with an FDR <0.15 were included in a multiple regression model. Sixty three percent of patients achieved an absolute PASI ≤1 at 6 months, while 71% did so after 12 months. Disease duration (.